Psychiatry Unit, Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Psychiatry Unit, Department of Medical and Surgical Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Int J Psychiatry Clin Pract. 2020 Jun;24(2):201-207. doi: 10.1080/13651501.2020.1737134. Epub 2020 Mar 5.
The main purpose of this study was to assess possible modifications of cognitive performance among schizophrenia patients treated with long-acting injectable antipsychotics (LAIs) of second generation anti-psychotics (SGAs). Our hypothesis is that the shift from the oral formulation to the LAI formulation of SGAs drugs improves the cognitive performance. The secondary objective was to carry out a head to head comparison of two different SGA-LAI treatments [i.e., 1-month Paliperidone Palmitate (PP1M), monthly Aripiprazole (Ari-LAI)] in our study with an independent and real-world setting. The sample comprised 32 participants who were consecutively recruited over 12 months. Seventeen patients treated with Ari-LAI and 10 treated with PP1M completed psychopathological, neuropsychological and functional assessments. Group differences were explored through chi-squared and -tests, as appropriate. GLM Repeated Measures were used to study variations of cognitive performance along 12 months and to test differences between drugs. We found an effect of time on the outcomes investigated but this did not depend on the type of LAI used. In comparison with the previous oral treatment with SGAs, patients showed a significant improvement in neurocognitive function after 12 months of treatment with SGA-LAI. Furthermore, there were no differences between the SGA-LAI regimens.Key pointsThe main purpose of this study was to assess possible modification of cognitive performance of patients with Schizophrenia treated with second generation long-acting injectable antipsychotics (SGA-LAIs).The secondary objective was to carry out a head to head comparison of two different SGA-LAIs: Paliperidone Palmitate 1-Month (PP1M) and Aripiprazole Monthly (Ari-LAI).Patients showed a significant improvement in neurocognitive function after 12 months of treatment with SGA-LAI.There were no differences between the SGA-LAI regimens.From a practical point of view, switching to LAI formulation seems to produce further social and cognitive improvements in patients who had already benefitted from oral SGA therapy.
这项研究的主要目的是评估接受第二代长效注射抗精神病药物（SGAs-LAI）治疗的精神分裂症患者认知功能可能的变化。我们的假设是，从 SGA 药物的口服剂型向 LAI 剂型转变可以改善认知功能。次要目标是在我们的研究中，在独立的真实环境下，对头对头比较两种不同的 SGA-LAI 治疗[即 1 个月棕榈酸帕利哌酮（PP1M），每月阿立哌唑（Ari-LAI）]。该样本包括在 12 个月内连续招募的 32 名参与者。17 名接受 Ari-LAI 治疗的患者和 10 名接受 PP1M 治疗的患者完成了精神病理学、神经心理学和功能评估。通过适当的卡方和检验探索组间差异。GLM 重复测量用于研究 12 个月期间认知表现的变化，并测试药物之间的差异。我们发现结果存在时间效应，但这并不取决于所使用的 LAI 类型。与之前的 SGA 口服治疗相比，患者在接受 SGA-LAI 治疗 12 个月后神经认知功能显著改善。此外，两种 SGA-LAI 方案之间没有差异。关键点这项研究的主要目的是评估接受第二代长效注射抗精神病药物（SGA-LAI）治疗的精神分裂症患者认知功能的可能变化。次要目标是对头对头比较两种不同的 SGA-LAI：棕榈酸帕利哌酮 1 个月（PP1M）和阿立哌唑每月（Ari-LAI）。患者在接受 SGA-LAI 治疗 12 个月后神经认知功能显著改善。两种 SGA-LAI 方案之间无差异。从实际的角度来看，对于已经从 SGA 口服治疗中获益的患者，转向 LAI 剂型似乎会产生进一步的社会和认知改善。
